



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
OTC					
US	\$ 633	543	16.8%	16.8%	-
Intl	740	642	15.1%	14.9%	0.2%
WW	<u>1,373</u>	<u>1,185</u>	15.9%	15.8%	0.1%
SKIN HEALTH / BEAUTY					
US	538	583	-7.8%	-7.8%	-
Intl	546	594	-8.2%	-6.4%	-1.8%
WW	<u>1,084</u>	<u>1,177</u>	-8.0%	-7.1%	-0.9%
ORAL CARE					
US	159	173	-8.2%	-8.2%	-
Intl	246	264	-7.2%	-5.5%	-1.7%
WW	<u>405</u>	<u>437</u>	-7.6%	-6.5%	-1.1%
BABY CARE					
US	90	97	-7.5%	-7.5%	-
Intl	309	310	-0.3%	1.3%	-1.6%
WW	<u>399</u>	<u>407</u>	-2.0%	-0.8%	-1.2%
WOMEN'S HEALTH					
US	4	3	14.1%	14.1%	-
Intl	230	234	-1.8%	1.2%	-3.0%
WW	<u>233</u>	<u>237</u>	-1.6%	1.3%	-2.9%
WOUND CARE / OTHER					
US	106	110	-4.2%	-4.2%	-
Intl	57	65	-9.6%	-10.2%	0.6%
WW	<u>164</u>	<u>175</u>	-6.2%	-6.4%	0.2%
TOTAL CONSUMER HEALTH					
US	1,529	1,509	1.3%	1.3%	-
Intl	2,128	2,109	0.9%	2.1%	-1.2%
WW	<u>\$ 3,657</u>	<u>3,618</u>	1.1%	1.8%	-0.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	TWELVE MONTHS				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
OTC					
US	\$ 2,594	2,460	5.4%	5.4%	-
Intl	2,634	2,364	11.4%	6.9%	4.5%
WW	<u>5,227</u>	<u>4,824</u>	8.4%	6.2%	2.2%
SKIN HEALTH / BEAUTY					
US	2,400	2,350	2.1%	2.1%	-
Intl	2,141	2,100	1.9%	-0.3%	2.2%
WW	<u>4,541</u>	<u>4,450</u>	2.0%	1.0%	1.0%
ORAL CARE					
US	637	683	-6.7%	-6.7%	-
Intl	1,008	958	5.1%	2.8%	2.3%
WW	<u>1,645</u>	<u>1,641</u>	0.2%	-1.2%	1.4%
BABY CARE					
US	378	376	0.5%	0.5%	-
Intl	1,188	1,141	4.1%	3.7%	0.4%
WW	<u>1,566</u>	<u>1,517</u>	3.2%	2.9%	0.3%
WOMEN'S HEALTH					
US	13	13	-1.6%	-1.6%	-
Intl	905	888	1.8%	2.0%	-0.2%
WW	<u>917</u>	<u>901</u>	1.8%	1.9%	-0.1%
WOUND CARE / OTHER					
US	495	480	3.1%	3.1%	-
Intl	243	240	1.7%	-2.7%	4.4%
WW	<u>739</u>	<u>720</u>	2.6%	1.2%	1.4%
TOTAL CONSUMER HEALTH					
US	6,516	6,362	2.4%	2.4%	-
Intl	8,119	7,691	5.6%	3.1%	2.5%
WW	<u>\$ 14,635</u>	<u>14,053</u>	4.1%	2.8%	1.3%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
PHARMACEUTICAL SEGMENT ^(2,3)					
IMMUNOLOGY					
US	\$ 2,912	2,845	2.4%	2.4%	-
Intl	1,443	1,261	14.5%	17.9%	-3.4%
WW	<u>4,355</u>	<u>4,105</u>	6.1%	7.1%	-1.0%
REMICADE					
US	511	656	-22.2%	-22.2%	-
US Exports ⁽⁴⁾	39	25	53.5%	53.5%	-
Intl	214	220	-2.3%	-2.4%	0.1%
WW	<u>764</u>	<u>901</u>	-15.2%	-15.2%	0.0%
SIMPONI / SIMPONI ARIA					
US	287	315	-8.9%	-8.9%	-
Intl	271	261	3.6%	8.4%	-4.8%
WW	<u>559</u>	<u>576</u>	-3.2%	-1.0%	-2.2%
STELARA					
US	1,542	1,572	-1.9%	-1.9%	-
Intl	792	672	17.9%	21.7%	-3.8%
WW	<u>2,334</u>	<u>2,244</u>	4.0%	5.1%	-1.1%
TREMFYA					
US	528	276	90.9%	90.9%	-
Intl	165	105	56.9%	61.8%	-4.9%
WW	<u>693</u>	<u>382</u>	81.5%	82.8%	-1.3%
OTHER IMMUNOLOGY					
US	6	-	*	*	-
Intl	0	2	*	*	*
WW	<u>6</u>	<u>2</u>	*	*	*
INFECTIOUS DISEASES					
US	614	470	30.8%	30.8%	-
Intl	1,824	442	*	*	-3.0%
WW	<u>2,437</u>	<u>912</u>	*	*	-1.5%
COVID-19 VACCINE					
US	213	-	*	*	-
Intl	1,405	-	*	*	-
WW	<u>1,619</u>	<u>-</u>	*	*	-
EDURANT / rilpivirine					
US	10	11	-15.8%	-15.8%	-
Intl	220	236	-6.8%	-3.3%	-3.5%
WW	<u>230</u>	<u>248</u>	-7.2%	-3.9%	-3.3%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA					
US	380	433	-12.2%	-12.2%	-
Intl	135	136	-0.1%	3.0%	-3.1%
WW	<u>515</u>	<u>569</u>	-9.3%	-8.5%	-0.8%
OTHER INFECTIOUS DISEASES					
US	11	25	-55.9%	-55.9%	-
Intl	63	71	-10.9%	-10.0%	-0.9%
WW	<u>74</u>	<u>96</u>	-22.9%	-22.2%	-0.7%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	TWELVE MONTHS				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
PHARMACEUTICAL SEGMENT ^(2,3)					
IMMUNOLOGY					
US	\$ 10,843	10,175	6.6%	6.6%	-
Intl	5,907	4,880	21.0%	17.7%	3.3%
WW	<u>16,750</u>	<u>15,055</u>	11.3%	10.2%	1.1%
REMICADE					
US	2,019	2,508	-19.5%	-19.5%	-
US Exports ⁽⁴⁾	236	346	-31.9%	-31.9%	-
Intl	935	893	4.8%	0.4%	4.4%
WW	<u>3,190</u>	<u>3,747</u>	-14.9%	-15.9%	1.0%
SIMPONI / SIMPONI ARIA					
US	1,127	1,155	-2.4%	-2.4%	-
Intl	1,148	1,088	5.5%	4.1%	1.4%
WW	<u>2,276</u>	<u>2,243</u>	1.4%	0.8%	0.6%
STELARA					
US	5,938	5,240	13.3%	13.3%	-
Intl	3,196	2,467	29.6%	25.9%	3.7%
WW	<u>9,134</u>	<u>7,707</u>	18.5%	17.3%	1.2%
TREMFYA					
US	1,503	926	62.3%	62.3%	-
Intl	624	421	48.2%	44.0%	4.2%
WW	<u>2,127</u>	<u>1,347</u>	57.9%	56.5%	1.4%
OTHER IMMUNOLOGY					
US	21	-	*	*	-
Intl	3	11	-73.3%	-74.6%	1.3%
WW	<u>24</u>	<u>11</u>	*	*	*
INFECTIOUS DISEASES					
US	2,249	1,735	29.7%	29.7%	-
Intl	3,612	1,839	96.3%	93.4%	2.9%
WW	<u>5,861</u>	<u>3,574</u>	64.0%	62.5%	1.5%
COVID-19 VACCINE					
US	634	-	*	*	-
Intl	1,751	-	*	*	-
WW	<u>2,385</u>	<u>-</u>	*	*	-
EDURANT / rilpivirine					
US	41	44	-7.6%	-7.6%	-
Intl	953	920	3.6%	0.4%	3.2%
WW	<u>994</u>	<u>964</u>	3.1%	0.0%	3.1%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA					
US	1,508	1,587	-4.9%	-4.9%	-
Intl	575	597	-3.6%	-6.0%	2.4%
WW	<u>2,083</u>	<u>2,184</u>	-4.6%	-5.2%	0.6%
OTHER INFECTIOUS DISEASES					
US	66	104	-36.0%	-36.0%	-
Intl	333	323	3.0%	-0.1%	3.1%
WW	<u>399</u>	<u>427</u>	-6.5%	-8.9%	2.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE					
US	899	806	11.4%	11.4%	-
Intl	894	892	0.2%	3.2%	-3.0%
WW	<u>1,793</u>	<u>1,698</u>	5.5%	7.1%	-1.6%
<u>CONCERTA / Methylphenidate</u>					
US	55	33	68.1%	68.1%	-
Intl	123	120	3.2%	6.0%	-2.8%
WW	<u>178</u>	<u>153</u>	17.2%	19.4%	-2.2%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	668	610	9.5%	9.5%	-
Intl	361	355	1.5%	5.0%	-3.5%
WW	<u>1,029</u>	<u>965</u>	6.5%	7.8%	-1.3%
<u>RISPERDAL CONSTA</u>					
US	77	76	2.3%	2.3%	-
Intl	63	92	-30.3%	-26.4%	-3.9%
WW	<u>140</u>	<u>167</u>	-15.6%	-13.4%	-2.2%
<u>OTHER NEUROSCIENCE</u>					
US	99	88	11.7%	11.7%	-
Intl	346	326	6.2%	8.6%	-2.4%
WW	<u>445</u>	<u>414</u>	7.4%	9.2%	-1.8%
ONCOLOGY					
US	1,594	1,469	8.5%	8.5%	-
Intl	2,184	1,965	11.1%	15.2%	-4.1%
WW	<u>3,778</u>	<u>3,434</u>	10.0%	12.3%	-2.3%
<u>DARZALEX</u>					
US	867	692	25.3%	25.3%	-
Intl	778	561	38.9%	43.5%	-4.6%
WW	<u>1,645</u>	<u>1,253</u>	31.4%	33.4%	-2.0%
<u>ERLEADA</u>					
US	235	176	33.4%	33.4%	-
Intl	149	64	*	*	*
WW	<u>384</u>	<u>241</u>	59.8%	61.3%	-1.5%
<u>IMBRUVICA</u>					
US	436	492	-11.3%	-11.3%	-
Intl	626	625	0.0%	3.4%	-3.4%
WW	<u>1,062</u>	<u>1,117</u>	-5.0%	-3.1%	-1.9%
<u>ZYTIGA / abiraterone acetate</u>					
US	23	89	-74.2%	-74.2%	-
Intl	525	533	-1.4%	3.1%	-4.5%
WW	<u>548</u>	<u>622</u>	-11.8%	-7.9%	-3.9%
<u>OTHER ONCOLOGY</u>					
US	34	20	64.7%	64.7%	-
Intl	106	183	-42.0%	-39.2%	-2.8%
WW	<u>140</u>	<u>202</u>	-31.3%	-28.8%	-2.5%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	TWELVE MONTHS				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE					
US	3,347	3,091	8.3%	8.3%	-
Intl	3,664	3,457	6.0%	3.9%	2.1%
WW	<u>7,011</u>	<u>6,548</u>	7.1%	5.9%	1.2%
<u>CONCERTA / Methylphenidate</u>					
US	172	183	-5.8%	-5.8%	-
Intl	495	439	12.8%	10.1%	2.7%
WW	<u>667</u>	<u>622</u>	7.3%	5.4%	1.9%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	2,550	2,314	10.2%	10.2%	-
Intl	1,472	1,339	10.0%	6.9%	3.1%
WW	<u>4,022</u>	<u>3,653</u>	10.1%	9.0%	1.1%
<u>RISPERDAL CONSTA</u>					
US	287	296	-2.9%	-2.9%	-
Intl	305	346	-11.8%	-13.1%	1.3%
WW	<u>592</u>	<u>642</u>	-7.7%	-8.4%	0.7%
<u>OTHER NEUROSCIENCE</u>					
US	338	298	13.3%	13.3%	-
Intl	1,391	1,334	4.3%	3.2%	1.1%
WW	<u>1,729</u>	<u>1,632</u>	6.0%	5.0%	1.0%
ONCOLOGY					
US	5,958	5,092	17.0%	17.0%	-
Intl	8,590	7,275	18.1%	15.3%	2.8%
WW	<u>14,548</u>	<u>12,367</u>	17.6%	16.0%	1.6%
<u>DARZALEX</u>					
US	3,169	2,232	42.0%	42.0%	-
Intl	2,854	1,958	45.8%	42.6%	3.2%
WW	<u>6,023</u>	<u>4,190</u>	43.8%	42.3%	1.5%
<u>ERLEADA</u>					
US	813	583	39.3%	39.3%	-
Intl	478	176	*	*	*
WW	<u>1,291</u>	<u>760</u>	70.0%	68.7%	1.3%
<u>IMBRUVICA</u>					
US	1,747	1,821	-4.0%	-4.0%	-
Intl	2,622	2,307	13.6%	10.4%	3.2%
WW	<u>4,369</u>	<u>4,128</u>	5.8%	4.1%	1.7%
<u>ZYTIGA / abiraterone acetate</u>					
US	119	373	-68.1%	-68.1%	-
Intl	2,178	2,097	3.9%	1.5%	2.4%
WW	<u>2,297</u>	<u>2,470</u>	-7.0%	-9.0%	2.0%
<u>OTHER ONCOLOGY</u>					
US	110	83	31.7%	31.7%	-
Intl	458	738	-37.9%	-38.7%	0.8%
WW	<u>568</u>	<u>821</u>	-30.8%	-31.5%	0.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>PULMONARY HYPERTENSION</u>					
US	587	592	-0.7%	-0.7%	-
Intl	264	273	-3.6%	0.8%	-4.4%
WW	851	865	-1.6%	-0.2%	-1.4%
<u>OPSUMIT</u>					
US	286	279	2.0%	2.0%	-
Intl	162	173	-6.1%	-1.7%	-4.4%
WW	448	452	-1.1%	0.6%	-1.7%
<u>UPTRAVI</u>					
US	264	263	0.0%	0.0%	-
Intl	46	38	21.9%	24.7%	-2.8%
WW	310	301	2.7%	3.1%	-0.4%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	38	49	-20.1%	-20.1%	-
Intl	56	63	-12.2%	-6.6%	-5.6%
WW	94	112	-15.6%	-12.4%	-3.2%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	813	935	-13.1%	-13.1%	-
Intl	261	317	-17.8%	-16.0%	-1.8%
WW	1,074	1,253	-14.3%	-13.8%	-0.5%
<u>XARELTO</u>					
US	644	629	2.5%	2.5%	-
Intl	-	-	-	-	-
WW	644	629	2.5%	2.5%	-
<u>INVOKANA / INVOKAMET</u>					
US	59	159	-63.1%	-63.1%	-
Intl	60	58	3.8%	4.5%	-0.7%
WW	120	217	-45.1%	-44.9%	-0.2%
<u>PROCRIT / EPREX</u>					
US	55	62	-12.8%	-12.8%	-
Intl	58	66	-13.0%	-11.7%	-1.3%
WW	113	129	-12.9%	-12.2%	-0.7%
<u>OTHER</u>					
US	55	85	-35.6%	-35.6%	-
Intl	143	194	-25.9%	-23.8%	-2.1%
WW	198	278	-28.9%	-27.4%	-1.5%
<u>TOTAL PHARMACEUTICAL</u>					
US	7,418	7,116	4.2%	4.2%	-
Intl	6,870	5,152	33.4%	36.9%	-3.5%
WW	\$ 14,288	\$ 12,268	16.5%	17.9%	-1.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	TWELVE MONTHS				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>PULMONARY HYPERTENSION</u>					
US	2,365	2,133	10.9%	10.9%	-
Intl	1,085	1,015	6.9%	5.5%	1.4%
WW	3,450	3,148	9.6%	9.2%	0.4%
<u>OPSUMIT</u>					
US	1,147	1,008	13.7%	13.7%	-
Intl	672	631	6.6%	5.1%	1.5%
WW	1,819	1,639	11.0%	10.4%	0.6%
<u>UPTRAVI</u>					
US	1,056	955	10.5%	10.5%	-
Intl	181	138	31.1%	27.0%	4.1%
WW	1,237	1,093	13.1%	12.6%	0.5%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	163	169	-3.7%	-3.7%	-
Intl	232	247	-5.9%	-5.4%	-0.5%
WW	395	416	-5.0%	-4.7%	-0.3%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	3,192	3,509	-9.0%	-9.0%	-
Intl	1,268	1,369	-7.4%	-10.9%	3.5%
WW	4,460	4,878	-8.6%	-9.6%	1.0%
<u>XARELTO</u>					
US	2,438	2,345	4.0%	4.0%	-
Intl	-	-	-	-	-
WW	2,438	2,345	4.0%	4.0%	-
<u>INVOKANA / INVOKAMET</u>					
US	308	564	-45.4%	-45.4%	-
Intl	254	231	9.9%	5.4%	4.5%
WW	563	795	-29.3%	-30.6%	1.3%
<u>PROCRIT / EPREX</u>					
US	223	277	-19.7%	-19.7%	-
Intl	256	274	-6.8%	-10.1%	3.3%
WW	479	552	-13.3%	-14.9%	1.6%
<u>OTHER</u>					
US	223	323	-31.0%	-31.0%	-
Intl	758	864	-12.2%	-15.5%	3.3%
WW	981	1,186	-17.3%	-19.7%	2.4%
<u>TOTAL PHARMACEUTICAL</u>					
US	27,954	25,735	8.6%	8.6%	-
Intl	24,126	19,837	21.6%	18.8%	2.8%
WW	\$ 52,080	\$ 45,572	14.3%	13.1%	1.2%

MEDICAL DEVICES SEGMENT ⁽²⁾

INTERVENTIONAL SOLUTIONS

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
US	\$ 483	433	11.6%	11.6%	-
Intl	536	460	16.5%	18.8%	-2.3%
WW	1,019	893	14.1%	15.3%	-1.2%
<u>ORTHOPAEDICS</u>					
US	1,305	1,352	-3.5%	-3.5%	-
Intl	851	839	1.5%	3.9%	-2.4%
WW	2,155	2,191	-1.6%	-0.7%	-0.9%
<u>HIPS</u>					
US	229	229	0.4%	0.4%	-
Intl	151	143	4.9%	6.5%	-1.6%
WW	380	372	2.1%	2.7%	-0.6%
<u>KNEES</u>					
US	208	216	-4.2%	-4.2%	-
Intl	135	129	4.6%	6.5%	-1.9%
WW	342	345	-0.9%	-0.2%	-0.7%
<u>TRAUMA</u>					
US	467	454	2.8%	2.8%	-
Intl	261	268	-2.4%	0.7%	-3.1%
WW	728	722	0.9%	2.0%	-1.1%
<u>SPINE, SPORTS & OTHER</u>					
US	401	453	-11.4%	-11.4%	-
Intl	304	299	2.0%	4.3%	-2.3%
WW	706	752	-6.1%	-5.2%	-0.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	TWELVE MONTHS				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
	1,836	1,452	26.4%	26.4%	-
	2,135	1,594	34.0%	29.8%	4.2%
	3,971	3,046	30.4%	28.2%	2.2%
	5,126	4,779	7.3%	7.3%	-
	3,462	2,984	16.0%	12.1%	3.9%
	8,588	7,763	10.6%	9.1%	1.5%
	883	793	11.4%	11.4%	-
	602	487	23.6%	18.9%	4.7%
	1,485	1,280	16.0%	14.3%	1.7%
	787	743	5.9%	5.9%	-
	538	427	26.1%	21.7%	4.4%
	1,325	1,170	13.3%	11.7%	1.6%
	1,819	1,648	10.4%	10.4%	-
	1,066	966	10.4%	7.1%	3.3%
	2,885	2,614	10.4%	9.2%	1.2%
	1,637	1,595	2.6%	2.6%	-
	1,256	1,104	13.8%	9.9%	3.9%
	2,893	2,699	7.2%	5.6%	1.6%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
SURGERY					
US	986	1,002	-1.7%	-1.7%	-
Intl	1,527	1,427	7.0%	8.7%	-1.7%
WW	<u>2,513</u>	<u>2,429</u>	3.5%	4.4%	-0.9%
ADVANCED					
US	457	456	0.5%	0.5%	-
Intl	735	660	11.2%	12.6%	-1.4%
WW	<u>1,192</u>	<u>1,116</u>	6.8%	7.6%	-0.8%
GENERAL					
US	528	546	-3.4%	-3.4%	-
Intl	793	767	3.4%	5.3%	-1.9%
WW	<u>1,321</u>	<u>1,312</u>	0.6%	1.7%	-1.1%
VISION					
US	443	397	11.4%	11.4%	-
Intl	728	679	7.2%	10.8%	-3.6%
WW	<u>1,171</u>	<u>1,076</u>	8.7%	11.0%	-2.3%
CONTACT LENSES / OTHER					
US	316	289	9.4%	9.4%	-
Intl	518	507	1.9%	5.8%	-3.9%
WW	<u>833</u>	<u>796</u>	4.6%	7.1%	-2.5%
SURGICAL					
US	126	108	16.8%	16.8%	-
Intl	211	172	22.9%	25.4%	-2.5%
WW	<u>338</u>	<u>280</u>	20.5%	22.1%	-1.6%
TOTAL MEDICAL DEVICES					
US	3,216	3,184	1.0%	1.0%	-
Intl	3,643	3,405	7.0%	9.3%	-2.3%
WW	<u>\$ 6,859</u>	<u>6,589</u>	4.1%	5.3%	-1.2%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	TWELVE MONTHS				
	2021	2020	% Change		
		Reported	Operational ⁽¹⁾	Currency	
	3,867	3,249	19.0%	19.0%	-
	5,945	4,983	19.3%	15.6%	3.7%
	<u>9,812</u>	<u>8,232</u>	19.2%	17.0%	2.2%
	1,761	1,535	14.9%	14.9%	-
	2,861	2,304	24.1%	20.0%	4.1%
	<u>4,622</u>	<u>3,839</u>	20.4%	18.0%	2.4%
	2,105	1,714	22.7%	22.7%	-
	3,085	2,679	15.2%	11.8%	3.4%
	<u>5,190</u>	<u>4,392</u>	18.1%	16.1%	2.0%
	1,857	1,557	19.3%	19.3%	-
	2,831	2,362	19.8%	18.8%	1.0%
	<u>4,688</u>	<u>3,919</u>	19.6%	19.0%	0.6%
	1,398	1,213	15.2%	15.2%	-
	2,043	1,781	14.7%	14.0%	0.7%
	<u>3,440</u>	<u>2,994</u>	14.9%	14.5%	0.4%
	459	344	33.5%	33.5%	-
	788	581	35.7%	33.3%	2.4%
	<u>1,248</u>	<u>925</u>	34.9%	33.4%	1.5%
	12,686	11,036	14.9%	14.9%	-
	14,374	11,923	20.6%	17.3%	3.3%
	<u>\$ 27,060</u>	<u>22,959</u>	17.9%	16.2%	1.7%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

The Company estimates that the inclusion of an additional week in the 2020 fiscal year impacted fiscal fourth quarter 2021 comparative sales growth by approximately -4% and impacted full year fiscal 2021 comparative sales growth by approximately -1%.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales